71dee1fcb13293034d39b410a7a90475c028dc80ab59699cb2187e808da3185d

Product revenues (USD, millions)

Alliance revenues (USD, millions)

Royalty revenues (USD, millions)

Total revenues (USD, millions)

Cost of sales (USD, millions)

Selling, informational and administrative expenses (USD, millions)

Research and development expenses (USD, millions)

Acquired in-process research and development expenses (USD, millions)

Amortization of intangible assets (USD, millions)

Restructuring charges and certain acquisition-related costs (USD, millions)

Other (income)/deductions–net (USD, millions)

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) (USD, millions)

Provision/(benefit) for taxes on income/(loss) (USD, millions)

Income/(loss) from continuing operations (USD, millions)

Discontinued operations–net of tax (USD, millions)

Net income/(loss) before allocation to noncontrolling interests (USD, millions)

Less: Net income attributable to noncontrolling interests (USD, millions)

Net income/(loss) attributable to Pfizer Inc. common shareholders (USD, millions)

Earnings/(loss) per common share–basic from continuing operations attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–basic from discontinued operations–net of tax (USD)

Net earnings/(loss) per common share–basic attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–diluted from continuing operations attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–diluted from discontinued operations–net of tax (USD)

Net earnings/(loss) per common share–diluted attributable to Pfizer Inc. common shareholders (USD)

Weighted-average shares–basic (millions)

Weighted-average shares–diluted (millions)

5da3bd9eb89195adf041c65e86c177c589411a117627f1f5474386f87f495e5d

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from / Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

ce51e61505e23bf58898eb3a07e1f1dfe90caa220b01f0bc7f24730357f30994

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD, Per Share]

EPS - Diluted [USD, Per Share]

4fb5ce67fcd183f9b29ef684321f8ed6fc9d2a01961d0dbe1ba59cffa576e031

c4513f2be45492b34807906a81f173c607b35c8e367d98b8315b0472d1dd4abd

c49c0af84379bcb6aaa2fcd85d87ee3e1921696001fb0343dbbfcb0f730d12ba

e78bce242172fad841e199fcdc9a9f83c3f6d5aa7e6c4a7161b8a49dc225c061

United States

International

- Developed Markets

- Emerging Markets

Developed Europe

Developed Rest of World

Total Revenue

433815e0d4f218cda3546f8f976f4ac314cffe22d428249bfd25ae85b1039715

Pfizer Inc (PFE)

Financials